The cellular proteasome is an important molecular target in cancer therapy and drug resistance research.
Proteasome inhibitors are effective agents against multiple myeloma and mantle cell lymphoma and display great potential as treatment for a variety of other malignancies.
The proteasome is a large multicatalytic, proteinase complex located in the cytosol and the nucleus of eukaryotic cells.
The ubiquitin proteasome system is responsible for the degradation of most intracellular proteins and therefore plays an essential regulatory role in critical cellular processes including cell cycle progression, proliferation, differentiation, angiogenesis, and apoptosis.
Cancer cells are particularly sensitive to proteasome inhibitors, indicating the utility for inhibition of the ubiquitin-proteasome pathway as an approach for cancer therapy.
2012-03-30
Eng.
Clinical laboratory science : journal of the American Society for Medical Technology
Oakland University, School of Health Sciences, Biomedical Diagnostic and Therapeutic Sciences, Rochester, MI 48309, USA. landispi [at] oakland.edu
Clin Lab Sci. 2012 ;25(1):38-44
© Galenicom 1999-2013